RELMADA THERAPEUTICS, INC.
RLMDDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
RLMD Earnings Report
EPS Est: $-0.21 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
How RLMD's past catalysts played out
REL-1017
Depressive Disorder, Major
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel
Non Muscle Invasive Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
REL-1017 | Phase 3 | Depressive Disorder, Major | - | - |
NDV01 intravesical controlled release formulation of gemcitabine and docetaxel | Phase 2 | Non Muscle Invasive Bladder Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in RELMADA THERAPEUTICS, INC.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in RELMADA THERAPEUTICS, INC.'s (RLMD) pipeline across Phase 3, Phase 2. Its lead program is REL-1017 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is RELMADA THERAPEUTICS, INC.'s next FDA catalyst?→
RELMADA THERAPEUTICS, INC.'s (RLMD) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RLMD biotech catalysts?→
Add RLMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RELMADA THERAPEUTICS, INC.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.